Disclosures: Parissa Tabrizian: AstraZeneca: Speaking and Teaching, Aztrazeneca: Speaking and Teaching, Boston Scientific: Speaking and Teaching, Matthew Holzner: Nothing to Disclose, Edison Xu: Nothing to Disclose, Maarouf Hoteit: HepQuant, LLC: Advisor, Veeral Ajmera: Nothing to Disclose, Tara Ghaziani: Nothing to Disclose, Neehar Parikh: Genentech: Grant/Research Support, Exelixis: Grant/Research Support, Exelixis: Consultant, AstraZeneca: Consultant, Exact Sciences: Grant/Research Support, Exact Sciences: Consultant, Fujifilm Medical: Advisor, Kali Zhou: Gilead Sciences Inc: Grant/Research Support, Amy Kim: Nothing to Disclose, Rebecca Marino: Nothing to Disclose, Francis Yao: Nothing to Disclose, Sander Florman: Nothing to Disclose, Neil Mehta: Merck: Consultant, FujiFilm WAKO: Consultant 444 TARGETING THE LIVER CLOCK IMPROVES FIBROSIS BY RESTORATION OF TGF-&BETA
In general, using these compounds is expected to be a new pathway to developing drugs for IS by suppressing ferroptosis
CrossRef Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population Jean-Bonny Nsumbu, Jean-Robert Makulo, Trsor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi Hepatic Medicine: Evidence and Research .2025
Metabolomics measures the chemical products of these genes and the enzymes they produce
If the ligand is a protein or peptide that has no free sulfhydryl groups but that does have a disulde bond, this bond can be reduced to allow ligand attachment
